Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs

Nicola B. Mercuri, Antonello Bonci, Giorgio Bernardi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

It is generally accepted that the dopamine receptor ligands currently used in the treatment of parkinsonian symptoms mainly stimulate dopamine (DA) receptors of the D2 family to produce beneficial effects. Although several animal models can provide useful indications on the activity of the antiparkinsonian drugs in the brain, the specific cellular sites and the mechanism of action of these therapeutic agents are not completely known. In this article, Nicola Mercuri, Antonello Bonci and Giorgio Bernardi suggest that the electrophysiological effects of antiparkinsonian drugs on nigral dopaminergic cells are related to their clinical efficacy. In addition, they report that the stimulation of the D2 'autoreceptors' located on the residual dopamine-containing cells is implicated in the therapeutic response elicited by dopamine receptor agonists in parkinsonism. Thus, an electrophysiological approach, which can give basic information regarding the actions of direct and indirect DA receptor agonists on the dopaminergic neurones, might be relevant for the evolution of the pharmacological strategies in Parkinson's disease.

Original languageEnglish
Pages (from-to)232-235
Number of pages4
JournalTrends in Pharmacological Sciences
Volume18
Issue number7
DOIs
Publication statusPublished - Jul 1 1997

Fingerprint

Antiparkinson Agents
Autoreceptors
Dopamine Agonists
Pharmacology
Dopamine D2 Receptors
Dopaminergic Neurons
Dopamine Receptors
Parkinsonian Disorders
Substantia Nigra
Pharmaceutical Preparations
Neurons
Parkinson Disease
Dopamine
Brain
Animals
Animal Models
Ligands
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs. / Mercuri, Nicola B.; Bonci, Antonello; Bernardi, Giorgio.

In: Trends in Pharmacological Sciences, Vol. 18, No. 7, 01.07.1997, p. 232-235.

Research output: Contribution to journalArticle

@article{e7c8cbc2331f45e0a7f4e176412f9108,
title = "Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs",
abstract = "It is generally accepted that the dopamine receptor ligands currently used in the treatment of parkinsonian symptoms mainly stimulate dopamine (DA) receptors of the D2 family to produce beneficial effects. Although several animal models can provide useful indications on the activity of the antiparkinsonian drugs in the brain, the specific cellular sites and the mechanism of action of these therapeutic agents are not completely known. In this article, Nicola Mercuri, Antonello Bonci and Giorgio Bernardi suggest that the electrophysiological effects of antiparkinsonian drugs on nigral dopaminergic cells are related to their clinical efficacy. In addition, they report that the stimulation of the D2 'autoreceptors' located on the residual dopamine-containing cells is implicated in the therapeutic response elicited by dopamine receptor agonists in parkinsonism. Thus, an electrophysiological approach, which can give basic information regarding the actions of direct and indirect DA receptor agonists on the dopaminergic neurones, might be relevant for the evolution of the pharmacological strategies in Parkinson's disease.",
author = "Mercuri, {Nicola B.} and Antonello Bonci and Giorgio Bernardi",
year = "1997",
month = "7",
day = "1",
doi = "10.1016/S0165-6147(97)01079-1",
language = "English",
volume = "18",
pages = "232--235",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs

AU - Mercuri, Nicola B.

AU - Bonci, Antonello

AU - Bernardi, Giorgio

PY - 1997/7/1

Y1 - 1997/7/1

N2 - It is generally accepted that the dopamine receptor ligands currently used in the treatment of parkinsonian symptoms mainly stimulate dopamine (DA) receptors of the D2 family to produce beneficial effects. Although several animal models can provide useful indications on the activity of the antiparkinsonian drugs in the brain, the specific cellular sites and the mechanism of action of these therapeutic agents are not completely known. In this article, Nicola Mercuri, Antonello Bonci and Giorgio Bernardi suggest that the electrophysiological effects of antiparkinsonian drugs on nigral dopaminergic cells are related to their clinical efficacy. In addition, they report that the stimulation of the D2 'autoreceptors' located on the residual dopamine-containing cells is implicated in the therapeutic response elicited by dopamine receptor agonists in parkinsonism. Thus, an electrophysiological approach, which can give basic information regarding the actions of direct and indirect DA receptor agonists on the dopaminergic neurones, might be relevant for the evolution of the pharmacological strategies in Parkinson's disease.

AB - It is generally accepted that the dopamine receptor ligands currently used in the treatment of parkinsonian symptoms mainly stimulate dopamine (DA) receptors of the D2 family to produce beneficial effects. Although several animal models can provide useful indications on the activity of the antiparkinsonian drugs in the brain, the specific cellular sites and the mechanism of action of these therapeutic agents are not completely known. In this article, Nicola Mercuri, Antonello Bonci and Giorgio Bernardi suggest that the electrophysiological effects of antiparkinsonian drugs on nigral dopaminergic cells are related to their clinical efficacy. In addition, they report that the stimulation of the D2 'autoreceptors' located on the residual dopamine-containing cells is implicated in the therapeutic response elicited by dopamine receptor agonists in parkinsonism. Thus, an electrophysiological approach, which can give basic information regarding the actions of direct and indirect DA receptor agonists on the dopaminergic neurones, might be relevant for the evolution of the pharmacological strategies in Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=0030876571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030876571&partnerID=8YFLogxK

U2 - 10.1016/S0165-6147(97)01079-1

DO - 10.1016/S0165-6147(97)01079-1

M3 - Article

C2 - 9253853

AN - SCOPUS:0030876571

VL - 18

SP - 232

EP - 235

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 7

ER -